The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

Last updated: October 13, 2021
Sponsor: Sunshine Lake Pharma Co., Ltd.
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

Depression

Treatment

N/A

Clinical Study ID

NCT04984512
HEC113995-P-5
  • Ages 18-65
  • All Genders

Study Summary

This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 1.a Man or a woman with major depressive disorder(MDD) as the primary diagnosisaccording to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (classification code 296.22、296.23、296.32、296.33)
  • 2.Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greaterat Screening and Baseline Visits.
  • 3.Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greaterat Screening and Baseline Visits.

Exclusion

Exclusion Criteria:

  • 1.has major depressive disorder with psychotic features according to the DSM-5.
  • 2.Current or history of: bipolar disorder、schizophrenia、anixety disorder、insomnia、anysubstance abuse or dependence and other psychiatry disorder as defined in the DSM-5.
  • 3.Current or history of a clinically significant neurological disorder (includingepilepsy、Alzheimer disease, Parkinson disease, multiple sclerosis, Huntingtondisease).
    1. has Serious body disease such as neurological disorders、cardiacvasculardisorders、hepatic disorders、 renal disorders, blood system disorders and endocrinedisorders.
    1. Current or history of cancer( except basal cell of the skin and preinvasivecarcinoma of cervix uteri).
    1. Current or history of angle-closure glaucoma.
    1. has made a suicide behavior in the previous 1 year ,or has a score greater than orequal to 4 on item 10 (suicidal thoughts) of MADRS .
  • 8.has taken fluoxetine within 4 weeks prior to initial dosing.
    1. has taken other antidepressive medications or antipsychotic medications within 2weeks prior to initial dosing.
  • 10.has psychotherap at Screening and/or Baseline Visits.
  • 11.has had physiotherapy within 3 months prior to initial dosing.
  • 12.Has an alanine aminotransferase, aspartate aminotransferase or total bilirubinlevel greater than 1.5 times the upper limits of normal.
  • 13.Has an alanine aminotransferase, aspartate aminotransferase level greater than 2times the upper limits of normal;or total bilirubin, direct bilirubin,creatinine levelgreater than 1.5 times the upper limits of normal;or a thyroid stimulating hormonevalue outside the normal range.
  • 14.Has an abnormal electrocardiogram confirmed as clinically significant by theinvestigator.
  • 15.Has a history of severe allergies.

Study Design

Total Participants: 600
Study Start date:
November 01, 2021
Estimated Completion Date:
May 31, 2024